Future perspectives in melanoma research-Reference-Cited by-同舟云学术

Future perspectives in melanoma research

Published:2016-11-15 Issue:1 Volume:14 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Ascierto Paolo A.,Agarwala Sanjiv,Botti Gerardo,Cesano Alessandra,Ciliberto Gennaro,Davies Michael A.,Demaria Sandra,Dummer Reinhard,Eggermont Alexander M.,Ferrone Soldano,Fu Yang Xin,Gajewski Thomas F.,Garbe Claus,Huber Veronica,Khleif Samir,Krauthammer Michael,Lo Roger S.,Masucci Giuseppe,Palmieri Giuseppe,Postow Michael,Puzanov Igor,Silk Ann,Spranger Stefani,Stroncek David F.,Tarhini Ahmad,Taube Janis M.,Testori Alessandro,Wang Ena,Wargo Jennifer A.,Yee Cassian,Zarour Hassane,Zitvogel Laurence,Fox Bernard A.,Mozzillo Nicola,Marincola Francesco M.,Thurin Magdalena

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12967-016-1070-y.pdf

Reference147 articles.

1. Cancer Genome Atlas. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–96. doi: 10.1016/j.cell.2015.05.044 .

2. Bucheit AD, Chen G, Siroy A, et al. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014;20(21):5527–36. doi: 10.1158/1078-0432.CCR-14-1027 .

3. Chen G, Chakravarti N, Aardalen K, et al. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res. 2014;20(21):5537–46. doi: 10.1158/1078-0432.CCR-13-3003 .

4. Gopal YN, Rizos H, Chen G, et al. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1alpha and oxidative phosphorylation in melanoma. Cancer Res. 2014;74(23):7037–47. doi: 10.1158/0008-5472.CAN-14-1392 .

5. Peng W, Chen JQ, Liu C, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6(2):202–16. doi: 10.1158/2159-8290.CD-15-0283 .

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Immunotherapy;Holland‐Frei Cancer Medicine;2022-10-21

2. A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies;Frontiers in Pharmacology;2021-03-29

3. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma;BMC Cancer;2020-01-28

4. Sequential Treatment With Targeted and Immune Checkpoint Therapy in Patients With BRAF Positive Metastatic Melanoma: The Importance of Timing?;Frontiers in Medicine;2019-12-17

5. Holistic view of patients with melanoma of the skin: how can health systems create value and achieve better clinical outcomes?;ecancermedicalscience;2019-08-27